Education
About Us
Working with TipRanks
Follow Us
Viatris, Inc. (VTRS)
:VTRS
VTRS Stock Chart & Stats
$11.93
>-$0.01(-0.04%)
At close: 4:00 PM EST
$11.93
>-$0.01(-0.04%)
Day’s Range― - ―
52-Week Range$6.85 - $12.68
Previous CloseN/A
Volume2.11M
Average Volume (3M)7.93M
Market Cap
$13.74B
Enterprise Value$26.82B
Total Cash (Recent Filing)$1.16B
Total Debt (Recent Filing)$14.72B
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Mar 02, 2026EPS Estimate
0.54Next Dividend Ex-DateN/A
Dividend Yield4.02%
Share Statistics
EPS (TTM)0.67
Shares Outstanding1,151,769,900
10 Day Avg. Volume8,454,494
30 Day Avg. Volume7,929,138
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.80
Price to Sales (P/S)1.01
P/FCF Ratio7.52
Enterprise Value/Market Cap1.95
Enterprise Value/Revenue1.90
Enterprise Value/Gross Profit5.26
Enterprise Value/Ebitda-44.78
Forecast
1Y Price Target
$12.00Price Target Upside0.59% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)2.31
Revenue Forecast (FY)$14.08B
Bulls Say, Bears Say
Bulls Say
Leadership And Strategic InitiativesThe direction of the company is undergoing an affirmative change under the refreshed leadership team supported by a market leading branded portfolio, a progressive generics foothold, and a robust pipeline with blockbuster potential.
Market Position And Product PipelineThe company's transition into an increasingly reputable global specialty pharma with a generics and branded base business supports leverage for new product additions.
Strategic Plan CompletionThe company is nearing completion of its 'Phase 1' strategic plan that includes stabilizing the base business, growing the pipeline, and reducing debt.
Bears Say
Manufacturing Compliance IssuesViatris is facing a manufacturing overhang at its Indore, India facility after receiving a Warning Letter and a US Import Ban on 11 products due to poor quality controls and inadequate handling of manufacturing errors.
Regulatory And Pricing RisksRisks include regulation and pricing uncertainty, litigation, regulatory scrutiny of manufacturing compliance, and potential spillover to other facilities.
Viatris News
VTRS FAQ
What was Viatris, Inc.’s price range in the past 12 months?
Viatris, Inc. lowest stock price was $6.85 and its highest was $12.68 in the past 12 months.
What is Viatris, Inc.’s market cap?
Viatris, Inc.’s market cap is $13.74B.
When is Viatris, Inc.’s upcoming earnings report date?
Viatris, Inc.’s upcoming earnings report date is Mar 02, 2026 which is in 71 days.
How were Viatris, Inc.’s earnings last quarter?
Viatris, Inc. released its earnings results on Nov 06, 2025. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.621 by $0.049.
Is Viatris, Inc. overvalued?
According to Wall Street analysts Viatris, Inc.’s price is currently Undervalued.
Does Viatris, Inc. pay dividends?
Viatris, Inc. pays a Quarterly dividend of $0.12 which represents an annual dividend yield of 4.02%. See more information on Viatris, Inc. dividends here
What is Viatris, Inc.’s EPS estimate?
Viatris, Inc.’s EPS estimate is 0.54.
How many shares outstanding does Viatris, Inc. have?
Viatris, Inc. has 1,151,769,900 shares outstanding.
What happened to Viatris, Inc.’s price movement after its last earnings report?
Viatris, Inc. reported an EPS of $0.67 in its last earnings report, beating expectations of $0.621. Following the earnings report the stock price went down -6.021%.
Which hedge fund is a major shareholder of Viatris, Inc.?
Currently, no hedge funds are holding shares in VTRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viatris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.00 (0.59% Upside)
$12.00 (0.59% Upside)
Blogger Sentiment
Neutral
VTRS Sentiment 50%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 4.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.35%
12-Months-Change
Fundamentals
Return on Equity
-21.09%
Trailing 12-Months
Asset Growth
-15.27%
Trailing 12-Months
Company Description
Viatris, Inc.
Viatris Inc. (VTRS) is a global healthcare company formed through the merger of Mylan N.V. and Upjohn, a division of Pfizer. The company operates in the pharmaceutical sector and focuses on providing access to medicines, including generic and branded medications, as well as over-the-counter products. Viatris aims to empower people worldwide by offering a diverse portfolio that includes treatments for chronic conditions, infectious diseases, and other therapeutic areas.
VTRS Company Deck
VTRS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of strong commercial performance in certain segments and strategic advancements in R&D, offset by challenges related to the Indore facility and specific market declines. The company is actively addressing these issues and making progress in its strategic initiatives.View all VTRS earnings summariesVTRS Net sales Breakdown
62.62% Brands
37.38% Generics
VTRS Stock 12 Month Forecast
Average Price Target
$12.00
▲(0.59% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Ownership Overview
0.25% Insiders
27.02% Mutual Funds
19.51% Other Institutional Investors
24.89% Public Companies and Individual Investors